INDICATIONS

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request
a Rep

Sitemap

Homepage

LR-MDS-RS (Second-line)

PATIENT IDENTIFICATION

PATIENT OUTCOMES

DOSING AND ADMINISTRATION

SUPPORT AND RESOURCES

Beta-thalassemia

THE NEED FOR REBLOZYL

PATIENT OUTCOMES

DOSING AND ADMINISTRATION

SUPPORT AND RESOURCES

Sitemap

Homepage

LR-MDS-RS (Second-line)

PATIENT IDENTIFICATION

PATIENT OUTCOMES

DOSING AND ADMINISTRATION

SUPPORT AND RESOURCES

Beta-thalassemia

THE NEED FOR REBLOZYL

PATIENT OUTCOMES

DOSING AND ADMINISTRATION

SUPPORT AND RESOURCES